Allogeneic Hematopoietic Cell Transplantation
8
2
2
3
Key Insights
Highlights
Success Rate
60% trial completion
Clinical Risk Assessment
Based on trial outcomes
High Risk
Score: 75/100
25.0%
2 terminated out of 8 trials
60.0%
-26.5% vs benchmark
0%
0 trials in Phase 3/4
67%
2 of 3 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 3 completed trials
Clinical Trials (8)
Study of Nicotinamide Riboside Supplementation in Allogeneic Hematopoietic Cell Transplantation
Precision Alemtuzumab Dosing for Allogeneic Hematopoietic Cell Transplantation
A Study of FMT in Patients With AML Allo HSCT in Recipients
TCRαβ+/CD19+ Depleted Allogeneic Hematopoietic Stem Cell Transplantation for Malignant and Non-malignant Disorders
Xylitol - Healthcare Associated Infection Reduction in Stem Cell Transplant Patients
Precision Dosing of Alemtuzumab
Iron Overload in Patients Undergoing Donor Stem Cell Transplant
The Effect of Folinic Acid Rescue Following MTX GVHD Prophylaxis on Regimen Related Toxicity and Transplantation Outcome